article
Keith Murphy, CEO of Viscient Biosciences, discusses the process of…
19 June 2020 | By Hannah Balfour (Drug Target Review)
Keith Murphy, CEO of Viscient Biosciences, discusses the process of developing a 3D bioprinted tissue model and their potential in developing therapeutics for COVID-19 and other diseases.